Health expenditure comparison of extended-release metoprolol succinate and immediate-release metoprolol tartarate

ClinicoEconomics and Outcomes Research

Volumn 4, Issue 1, 2012, Pages 49-56

  Vaidya, Varun ^a   Patel, Pranav ^a  

^a UNIVERSITY OF TOLEDO   (United States)

Author keywords

Cost; Hypertension; Propensity score

Indexed keywords

METOPROLOL SUCCINATE; METOPROLOL TARTRATE;

ADULT; AGED; ARTICLE; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; COST CONTROL; DRUG COST; DRUG USE; FEMALE; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; SOCIAL STATUS;

EID: 84857316564     PISSN: None     EISSN: 11786981     Source Type: Journal    
DOI: 10.2147/CEOR.S27609     Document Type: Article

References (30)

1. Cushman WC. The burden of uncontrolled hypertension: morbidity and mortality associated with disease progression. J Clin Hypertens. 2003;5:14-22.
2. MacMahon S, Peto R, Collins R, et al. Blood pressure, stroke, and coronary heart disease. Part 1. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335:765-774.
3. Chobanian AV, Bakris GL, Black HR, et al.; for the Committee at NHBPEPC. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. JAMA. 2003;289:2560-2571.
4. Rosamond W, Flegal K, Friday G, et al; for the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2007 update. Circulation. 2007;115:e69-e171.
5. Heidenreich PA, Trogdon JG, Khavjou OA, et al. Forecasting the future of cardiovascular disease in the United States. Circulation. 2011;123:933-944.
6. Pittman DG, Tao Z, Chen W, Stettin GD. Antihypertensive medication adherence and subsequent healthcare utilization and costs. Am J Manag Care. 2010;16:568-576.
7. Ormond BA, Spillman BC, Waidmann TA, Caswell KJ, Tereshchenko B. Potential national and state medical care savings from primary disease prevention. Am J Public Health. 2011;101:157-164.
8. Lloyd-Jones DM, Evans JC, Levy D. Hypertension in adults across the age spectrum. JAMA. 2005;294:466-472.
9. Degli Esposti L, Valpiani G. Pharmacoeconomic burden of undertreating hypertension. Pharmacoeconomics. 2004;22:907-928.
10. Dusing R. Optimizing blood pressure control through the use of fixed combinations. Vasc Health Risk Manag. 2010;6:321-325.
11. Efacts. Facts and comparisons [website on the Internet]. Available from: http://www.efactsweb.com/index.asp. Accessed August 15, 2011.
12. Houtzagers JJ, Smilde JG, Creytens G, Westergren G. Efficacy and tolerability of a new controlled-release formulation of metoprolol: a comparison with conventional metoprolol tablets in mild to moderate hypertension. Eur J Clin Pharmacol. 1988;(33 Suppl):S39-S44.
13. Carruthers G, Shearer R, Taylor W, Moore M. A comparison of a controlled release (cr/zok) formulation of metoprolol, once daily, with conventional metoprolol tablets, twice daily, in mild to moderate hypertension. J Clin Pharmacol. 1990;30:S61-S65.
14. Redbook. Montvale, NJ: Thomson Healthcare; 2011.
15. Baser O. Too much ado about propensity score models? Comparing methods of propensity score matching. Value Health. 2006;9: 377-385.
16. Burnier M. Medication adherence and persistence as the cornerstone of effective antihypertensive therapy. Am J Hypertens. 2006;19: 1190-1196.
17. Schroeder K, Fahey T, Ebrahim S. How can we improve adherence to blood pressure-lowering medication in ambulatory care?: Systematic review of randomized controlled trials. Arch Intern Med. 2004;164: 722-732.
18. Andrejak M, Genes N, Vaur L, Poncelet P, Clerson P, Carre A. Electronic pill-boxes in the evaluation of antihypertensive treatment compliance: Comparison of once daily versus twice daily regimen. Am J Hypertens. 2000;13:184-190.
19. Baird MG, Bentley-Taylor MM, Carruthers SG, et al. A study of efficacy, tolerance and compliance of once-daily versus twice-daily metoprolol (betaloc) in hypertension. Betaloc compliance Canadian cooperative study group. Clin Invest Med. 1984;7:95-102.
20. Detry JM, Block P, De Backer G, Degaute JP. Patient compliance and therapeutic coverage: Comparison of amlodipine and slow release nifedipine in the treatment of hypertension. The Belgian collaborative study group. Eur J Clin Pharmacol. 1995;47:477-481.
21. Leenen FH, Wilson TW, Bolli P, et al. Patterns of compliance with once versus twice daily antihypertensive drug therapy in primary care: A randomized clinical trial using electronic monitoring. Can J Cardiol. 1997;13:914-920.
22. Girvin B, McDermott BJ, Johnston GD. A comparison of enalapril 20 mg once daily versus 10 mg twice daily in terms of blood pressure lowering and patient compliance. J Hypertens. 1999;17:1627-1631.
23. Cheng MM, Alfonso R, Best JH, Garrison LP, Bruhn D, Veenstra DL. The economic value of reducing medication dosing frequency with drug delivery technologies: an evidence assessment. J Med Econ. 2010;13:193-202.
24. Schroeder K, Fahey T, Hay AD, Montgomery A, Peters TJ. Relationship between medication adherence and blood pressure in primary care: prospective study. J Hum Hypertens. 2006;20:625-627.
25. Zannad F, Briancon S, Juilliere Y, et al. Incidence, clinical and etiologic features, and outcomes of advanced chronic heart failure: the EPICAL Study. Epidémiologie de l'Insuffisance Cardiaque Avancée en Lorraine. J Am Coll Cardiol. 1999;33:734-742.
26. Tu W, Morris AB, Li J, et al. Association between adherence measurements of metoprolol and health care utilization in older patients with heart failure. Clin Pharmacol Ther. 2005;77:189-201.
27. Braunschweig F, Cowie MR, Auricchio A. What are the costs of heart failure? Europace. 2011;13:ii13-ii17.
28. Rucker NL. $4 generics: how low, how broad, and why patient engagement is priceless. J Am Pharm Assoc (2003). 2010;50:761-763.
29. Hodgson TA, Cai L. Medical care expenditures for hypertension, its complications, and its comorbidities. Med Care. 2001;39: 599-615.
30. Hodgson TA, Cohen AJ. Medical care expenditures for selected circulatory diseases: opportunities for reducing national health expenditures. Med Care. 1999;37:994-1012.